Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Efaproxiral Sodium (RSR13 sodium) 是血红蛋白 (Hb) 合成变构调节剂,能够减少血红蛋白氧 (O2) 的结合亲和力。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 137 | 现货 | ||
10 mg | ¥ 186 | 现货 | ||
25 mg | ¥ 289 | 现货 | ||
50 mg | ¥ 413 | 现货 | ||
100 mg | ¥ 588 | 现货 | ||
200 mg | ¥ 879 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 455 | 现货 |
产品描述 | Efaproxiral Sodium (RSR13 sodium), a synthetic allosteric modifier of hemoglobin, is utilized for brain metastases originating from breast cancer. |
体外活性 | Efaproxiral, a synthetic allosteric modifier of hemoglobinoxygen binding affinity, has been shown to bind reversibly to hemoglobin, stabilizing the deoxyhemoglobin tetramer conformation to reduce its affinity for oxygen. [1] |
体内活性 | Efaproxiral plus oxygen breathing reduces the radiobiological hypoxic fraction of EMT6 tumors from the value of 24% found in both air-breathing and oxygen-breathing mice to 9% and improves the response of the tumors to radiation. Carboplatin (100 mg/kg) slowes tumor growth in air-breathing mice, producing a growth delay of 3.3 days. Efaproxiral plus oxygen increases the growth delay to 5.7 days; this is 2.4 days (71%) greater than that for carboplatin alone and 2.1 days (57%) greater than that for carboplatin plus oxygen breathing. Efaproxiral plus oxygen breathing, therefore, improves the tumor growth delay obtained with 100 mg/kg carboplatin to or beyond that obtained with the highly toxic dose of 150 mg/kg carboplatin, but does so without increasing the toxicity beyond that seen with 100 mg/kg carboplatin in air-breathing mice.[1] Efaproxiral significantly increases tumor oxygenation by 8.4 to 43.4 mmHg within 5 days in C3H mice with RIF-1 tumors, with maximum increases at 22-31 min after treatment. Efaproxiral plus oxygen plus Radiation produces tumor growth inhibition throughout the treatment duration in C3H mice with RIF-1 tumors, and inhibition is significantly different from radiation plus oxygen from day 3 to day 5. [2] |
别名 | 乙丙昔罗钠, RSR13 sodium |
分子量 | 363.38 |
分子式 | C20H23NO4·Na |
CAS No. | 170787-99-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 68 mg/mL (187.1 mM)
H2O: 67 mg/mL (184.4 mM)
Ethanol: 68 mg/mL (187.1 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / H2O / Ethanol | 1 mM | 2.7519 mL | 13.7597 mL | 27.5194 mL | 68.7985 mL |
5 mM | 0.5504 mL | 2.7519 mL | 5.5039 mL | 13.7597 mL | |
10 mM | 0.2752 mL | 1.376 mL | 2.7519 mL | 6.8799 mL | |
20 mM | 0.1376 mL | 0.688 mL | 1.376 mL | 3.4399 mL | |
50 mM | 0.055 mL | 0.2752 mL | 0.5504 mL | 1.376 mL | |
100 mM | 0.0275 mL | 0.1376 mL | 0.2752 mL | 0.688 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Efaproxiral Sodium 170787-99-2 Immunology/Inflammation Metabolism NF-Κb Reactive Oxygen Species RSR-13 乙丙昔罗钠 RSR13 RSR 13 RSR13 sodium Inhibitor inhibit Efaproxiral inhibitor